Skip to main content
SpringerLink
Log in

Using Placebo Response to Pain as a Predictor of Placebo Response in Mood Disorders

  • Mood and Anxiety Disorders (D Iosifescu, Section Editor)
  • Published:
Current Behavioral Neuroscience Reports Aims and scope Submit manuscript

Abstract

Recent Findings

Major depressive disorder (MDD) is the leading cause of disability worldwide and available pharmacological treatments are only partially effective. The development of new drugs is hindered by the high proportion of MDD patients who respond to placebo. Data from neuroimaging studies suggests convergence in the activation of brain circuits during placebo response to analgesia and placebo response in depression.

Purpose of Review

In the current work, we reviewed the published literature about placebo response in depression and in pain, focusing on the similarities within the neurobiological pathways that could facilitate identification of predictors of antidepressant placebo response.

Summary

Data suggests that placebo response in both pain and depression are mediated by reward neurocircuitry. The neuro-functional overlap between these networks suggests a novel strategy to prospectively identify placebo responders in MDD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547. doi:10.1371/journal.pmed.1001547.

    Article  PubMed  PubMed Central  Google Scholar 

  2. World Health Organization. Depr FACT Sheet. Retrieved from: http://www.who.int/mediacentre/factsheets/fs369/en/2016.

  3. Benedetti F, Carlino E, Piedimonte A. Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol. 2016;15(7):736–7. doi:10.1016/S1474-4422(16)00066-1 .A broad review of placebo response and its impact on research and medical practice within different CNS disorders

    Article  PubMed  Google Scholar 

  4. Kirsch I, Moore T, Scoboria A et al (2002) The emperor’s new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment 5(23). Retrieved from: http://alphachoices.com/repository/assets/pdf/EmperorsNewDrugs.pdf

  5. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734–50.

    Article  PubMed  Google Scholar 

  6. Ioannidis JP (2008) Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?. Philos Ethics Humanit Med 3:14–5341–3-14. doi: 10.1186/1747–5341–3-14

  7. Iovieno N, Papakostas GI. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2012;73(10):1300–6. doi:10.4088/JCP.11r07485.

    Article  PubMed  Google Scholar 

  8. Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry. 2011;72(4):464–72. doi:10.4088/JCP.10m06191.

    Article  PubMed  Google Scholar 

  9. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45. doi:10.1371/journal.pmed.0050045.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34–40. doi:10.1016/j.euroneuro.2008.08.009.

    Article  CAS  PubMed  Google Scholar 

  11. Rief W, Nestoriuc Y, Weiss S, et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord. 2009;118(1–3):1–8. doi:10.1016/j.jad.2009.01.029.

    Article  CAS  PubMed  Google Scholar 

  12. Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology. 2012;37(4):851–64. doi:10.1038/npp.2011.306.

    Article  CAS  PubMed  Google Scholar 

  13. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840–7.

    Article  PubMed  Google Scholar 

  14. Yan J (2012) Pipeline for new antidepressants flowing slowly. Psychiatric News. Retrieved from: http://psychnews.psychiatryonline.org/doi/full/10.1176%2Fpn.47.5.psychnews_47_5_1-b.

  15. Abbott A. Novartis to shut brain research facility. Nature. 2011;480(7376):161–2. doi:10.1038/480161a.

    Article  CAS  PubMed  Google Scholar 

  16. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203–14. doi:10.1038/nrd3078.

    CAS  PubMed  Google Scholar 

  17. Enck P, Klosterhalfen S. The placebo response in clinical trials-the current state of play. Complement Ther Med. 2013;21(2):98–101. doi:10.1016/j.ctim.2012.12.010.

    Article  PubMed  Google Scholar 

  18. Nitzan U, Bloch Y, Fennig S. Using placebo medications in the clinical setting—an intellectual game or a possible reality? Isr J Psychiatry Relat Sci. 2014;51(3):182–7.

    PubMed  Google Scholar 

  19. Fassler M, Meissner K, Schneider A et al (2010) Frequency and circumstances of placebo use in clinical practice—a systematic review of empirical studies. BMC Med 8:15–7015–8-15. doi: 10.1186/1741–7015–8-15

  20. Raz A, Campbell N, Guindi D, et al. Placebos in clinical practice: comparing attitudes, beliefs, and patterns of use between academic psychiatrists and nonpsychiatrists. Can J Psychiatr. 2011;56(4):198–208.

    Google Scholar 

  21. Chen GF, Johnson MH. Patients’ attitudes to the use of placebos: results from a New Zealand survey. N Z Med J. 2009;122(1296):35–46.

    PubMed  Google Scholar 

  22. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343–96. doi:10.1177/0269881107088441.

    Article  CAS  PubMed  Google Scholar 

  23. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–55. doi:10.1111/j.1399-5618.2009.00672.x.

    Article  CAS  PubMed  Google Scholar 

  24. American Psychiatric Association (2010) Practice guidelines for the treatment of patients with major depressive disorder. Retrieved from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf

  25. NICE (2009) Depression: the treatment and management of depression in adults. Retrieved from: http://www.nice.org.uk/CG090

  26. Fava M, Evins AE, Dorer DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115–27.

    Article  PubMed  Google Scholar 

  27. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979;8(1):7–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Mallinckrodt CH, Tamura RN, Tanaka Y. Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials. J Psychiatr Res. 2011;45(9):1202–7. doi:10.1016/j.jpsychires.2011.03.001.

    Article  PubMed  Google Scholar 

  29. Merlo-Pich E, Alexander RC, Fava M, et al. A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs. Clin Pharmacol Ther. 2010;88(5):634–42. doi:10.1038/clpt.2010.159.

    Article  CAS  PubMed  Google Scholar 

  30. Bech P, Kajdasz DK, Porsdal V. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology. 2006;188(3):273–80. doi:10.1007/s00213-006-0505-1.

    Article  CAS  PubMed  Google Scholar 

  31. Faries D, Herrera J, Rayamajhi J, et al. The responsiveness of the Hamilton depression rating scale. J Psychiatr Res. 2000;34(1):3–10.

    Article  CAS  PubMed  Google Scholar 

  32. Fava M, Mischoulon D, Iosifescu D, et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A study). Psychother Psychosom. 2012;81(2):87–97. doi:10.1159/000332050.

    Article  PubMed  Google Scholar 

  33. McIntyre RS, Konarski JZ, Mancini DA, et al. Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. CMAJ. 2005;173(11):1327–34.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Faries DE, Heiligenstein JH, Tollefson GD, et al. The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J Clin Psychopharmacol. 2001;21(6):561–8.

    Article  CAS  PubMed  Google Scholar 

  35. Lathyris DN, Trikalinos TA, Ioannidis JP. Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. Int J Epidemiol. 2007;36(2):422–30.

    Article  PubMed  Google Scholar 

  36. Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology. 1994;11(1):33–43. doi:10.1038/npp.1994.63.

    Article  CAS  PubMed  Google Scholar 

  37. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology. 2008;70(4):263–72.

    Article  PubMed  Google Scholar 

  38. Amanzio M, Benedetti F, Porro CA, et al. Activation likelihood estimation meta-analysis of brain correlates of placebo analgesia in human experimental pain. Hum Brain Mapp. 2013;34(3):738–52. doi:10.1002/hbm.21471 .A meta-analysis of brain imaging studies investigating the neural substrates of analgesic placebo response

    PubMed  Google Scholar 

  39. Kong J, Kaptchuk TJ, Polich G, et al. Placebo analgesia: findings from brain imaging studies and emerging hypotheses. Rev Neurosci. 2007;18(3–4):173–90.

    PubMed  Google Scholar 

  40. Vallance AK. A systematic review comparing the functional neuroanatomy of patients with depression who respond to placebo to those who recover spontaneously: is there a biological basis for the placebo effect in depression? J Affect Disord. 2007;98(1–2):177–85.

    Article  PubMed  Google Scholar 

  41. Wernicke JF, Ossanna MJ. The placebo response in pain and depression: in search of a common pathway. Front Biosci (Schol Ed). 2010;2:106–11.

    Article  Google Scholar 

  42. Geers AL, Wellman JA, Fowler SL, et al. Dispositional optimism predicts placebo analgesia. J Pain. 2010;11(11):1165–71. doi:10.1016/j.jpain.2010.02.014.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Schweinhardt P, Seminowicz DA, Jaeger E, et al. The anatomy of the mesolimbic reward system: a link between personality and the placebo analgesic response. J Neurosci. 2009;29(15):4882–7. doi:10.1523/JNEUROSCI.5634-08.2009.

    Article  CAS  PubMed  Google Scholar 

  44. Hall KT, Lembo AJ, Kirsch I, et al. Catechol-o-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One. 2012;7(10):e48135. doi:10.1371/journal.pone.0048135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Leuchter AF, McCracken JT, Hunter AM, et al. Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol. 2009;29(4):372–7. doi:10.1097/JCP.0b013e3181ac4aaf.

    Article  CAS  PubMed  Google Scholar 

  46. Mitchell LA, MacDonald RA, Brodie EE. Temperature and the cold pressor test. J Pain. 2004;5(4):233–7. doi:10.1016/j.jpain.2004.03.004.

    Article  PubMed  Google Scholar 

  47. Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010;71(5):616–26. doi:10.4088/JCP.09m05471blu.

    Article  CAS  PubMed  Google Scholar 

  48. Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010;30(2):135–44. doi:10.1097/JCP.0b013e3181d420a7.

    Article  CAS  PubMed  Google Scholar 

  49. Khan A, Kolts RL, Thase ME, et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry. 2004;161(11):2045–9.

    Article  PubMed  Google Scholar 

  50. Stein DJ, Baldwin DS, Dolberg OT, et al. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 2006;67(11):1741–6.

    Article  CAS  PubMed  Google Scholar 

  51. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53. doi:10.1001/jama.2009.1943.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Frank J, Frank J. Persuasion and healing: a comparative study of psychotherapy. Baltimore, MD: Johns Hopkins Press; 1991.

    Google Scholar 

  53. Kasper S, Dold M. Factors contributing to the increasing placebo response in antidepressant trials. World Psychiatry. 2015;14(3):304–6. doi:10.1002/wps.20245.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Rutherford BR, Wager TD, Roose SP. Expectancy and the treatment of depression: a review of experimental methodology and effects on patient outcome. Curr Psychiatr Rev. 2010;6(1):1–10. doi:10.2174/157340010790596571.

    Article  Google Scholar 

  55. Kraemer HC, Wilson GT, Fairburn CG, et al. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002;59(10):877–83.

    Article  PubMed  Google Scholar 

  56. Price DD, Milling LS, Kirsch I, et al. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain. 1999;83(2):147–56.

    Article  CAS  PubMed  Google Scholar 

  57. Voudouris NJ, Peck CL, Coleman G. The role of conditioning and verbal expectancy in the placebo response. Pain. 1990;43(1):121–8.

    Article  CAS  PubMed  Google Scholar 

  58. Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci. 2009;1156:198–210. doi:10.1111/j.1749-6632.2009.04424.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Benedetti F. What do you expect from this treatment? Changing our mind about clinical trials. Pain. 2007;128(3):193–4.

    Article  PubMed  Google Scholar 

  60. Sotsky SM, Glass DR, Shea MT, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH treatment of depression collaborative research program. Am J Psychiatry. 1991;148(8):997–1008. doi:10.1176/ajp.148.8.997.

    Article  CAS  PubMed  Google Scholar 

  61. Rutherford B, Sneed J, Devanand D, et al. Antidepressant study design affects patient expectancy: a pilot study. Psychol Med. 2010;40(5):781–8. doi:10.1017/S0033291709991085.

    Article  CAS  PubMed  Google Scholar 

  62. Krell HV, Leuchter AF, Morgan M, et al. Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. J Clin Psychiatry. 2004;65(9):1174–9.

    Article  PubMed  Google Scholar 

  63. Rutherford BR, Marcus SM, Wang P, et al. A randomized, prospective pilot study of patient expectancy and antidepressant outcome. Psychol Med. 2013;43(5):975–82. doi:10.1017/S0033291712001882.

    Article  CAS  PubMed  Google Scholar 

  64. Rutherford BR, Wall MM, Glass A, et al. The role of patient expectancy in placebo and nocebo effects in antidepressant trials. J Clin Psychiatry. 2014;75(10):1040–6. doi:10.4088/JCP.13m08797 .This paper describes experimental data documenting the direct impact of patients’ expectations of symptom change on reported depression severity

    Article  PubMed  PubMed Central  Google Scholar 

  65. Vase L, Petersen GL, Riley JL 3rd, et al. Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. Pain. 2009;145(1–2):36–44. doi:10.1016/j.pain.2009.04.008.

    Article  PubMed  Google Scholar 

  66. Elsenbruch S, Kotsis V, Benson S, et al. Neural mechanisms mediating the effects of expectation in visceral placebo analgesia: an fMRI study in healthy placebo responders and nonresponders. Pain. 2012;153(2):382–90. doi:10.1016/j.pain.2011.10.036.

    Article  PubMed  Google Scholar 

  67. Murray D, Stoessl AJ. Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. Pharmacol Ther. 2013;140(3):306–18. doi:10.1016/j.pharmthera.2013.07.009.

    Article  CAS  PubMed  Google Scholar 

  68. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999;19(1):484–94.

    CAS  PubMed  Google Scholar 

  69. Benedetti F, Arduino C, Amanzio M. Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci. 1999;19(9):3639–48.

    CAS  PubMed  Google Scholar 

  70. Wager TD, Rilling JK, Smith EE, et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science. 2004;303(5661):1162–7. doi:10.1126/science.1093065.

    Article  CAS  PubMed  Google Scholar 

  71. Benedetti F, Arduino C, Costa S, et al. Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain. 2006;121(1–2):133–44.

    Article  CAS  PubMed  Google Scholar 

  72. Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2010;35(1):4–26. doi:10.1038/npp.2009.129.

    Article  PubMed  Google Scholar 

  73. Lidstone SC, Stoessl AJ. Understanding the placebo effect: contributions from neuroimaging. Mol Imaging Biol. 2007;9(4):176–85. doi:10.1007/s11307-007-0086-3.

    Article  PubMed  Google Scholar 

  74. Collins KA, Schiller D. What can fear and reward learning teach us about depression? Curr Top Behav Neurosci. 2013;14:223–42. doi:10.1007/7854_2012_236

  75. de la Fuente-Fernandez R. The placebo-reward hypothesis: dopamine and the placebo effect. Parkinsonism Relat Disord. 2009;15(Suppl 3):S72–4. doi:10.1016/S1353-8020(09)70785-0.

    Article  PubMed  Google Scholar 

  76. Petrovic P, Kalso E, Petersson KM, et al. Placebo and opioid analgesia—imaging a shared neuronal network. Science. 2002;295(5560):1737–40. doi:10.1126/science.1067176.

    Article  CAS  PubMed  Google Scholar 

  77. Bingel U, Lorenz J, Schoell E, et al. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain. 2006;120(1–2):8–15.

    Article  CAS  PubMed  Google Scholar 

  78. Scott DJ, Stohler CS, Egnatuk CM, et al. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron. 2007;55(2):325–36.

    Article  CAS  PubMed  Google Scholar 

  79. Petrovic P, Kalso E, Petersson KM, et al. A prefrontal non-opioid mechanism in placebo analgesia. Pain. 2010;150(1):59–65. doi:10.1016/j.pain.2010.03.011.

    Article  PubMed  Google Scholar 

  80. Wager TD, Atlas LY, Leotti LA, et al. Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain experience. J Neurosci. 2011;31(2):439–52. doi:10.1523/JNEUROSCI.3420-10.2011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Wanigasekera V, Lee MC, Rogers R, et al. Baseline reward circuitry activity and trait reward responsiveness predict expression of opioid analgesia in healthy subjects. Proc Natl Acad Sci U S A. 2012;109(43):17705–10. doi:10.1073/pnas.1120201109.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. de la Fuente-Fernandez R, Schulzer M, Stoessl AJ. Placebo mechanisms and reward circuitry: clues from Parkinson’s disease. Biol Psychiatry. 2004;56(2):67–71. doi:10.1016/j.biopsych.2003.11.019.

    Article  PubMed  Google Scholar 

  83. Mayberg HS, Silva JA, Brannan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159(5):728–37. doi:10.1176/appi.ajp.159.5.728.

    Article  PubMed  Google Scholar 

  84. Leuchter AF, Morgan M, Cook IA, et al. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology. 2004;177(1–2):15–22. doi:10.1007/s00213-004-1919-2.

    Article  CAS  PubMed  Google Scholar 

  85. Pecina M, Bohnert AS, Sikora M, et al. Association between placebo-activated neural systems and antidepressant responses: neurochemistry of placebo effects in major depression. JAMA Psychiatry. 2015;72(11):1087–94. doi:10.1001/jamapsychiatry.2015.1335.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Sikora M, Heffernan J, Avery ET, et al. Salience network functional connectivity predicts placebo effects in major depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1(1):68–76. doi:10.1016/j.bpsc.2015.10.002 .An excellent paper investigating the neurocircuitry implicated in placebo response in depression

    Article  PubMed  Google Scholar 

  87. Petrovic P, Dietrich T, Fransson P, et al. Placebo in emotional processing--induced expectations of anxiety relief activate a generalized modulatory network. Neuron. 2005;46(6):957–69.

    Article  CAS  PubMed  Google Scholar 

  88. Lidstone SC, Schulzer M, Dinelle K, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry. 2010;67(8):857–65. doi:10.1001/archgenpsychiatry.2010.88.

    Article  CAS  PubMed  Google Scholar 

  89. Fields HL. Understanding how opioids contribute to reward and analgesia. Reg Anesth Pain Med. 2007;32(3):242–6.

    Article  CAS  PubMed  Google Scholar 

  90. Gradin VB, Kumar P, Waiter G, et al. Expected value and prediction error abnormalities in depression and schizophrenia. Brain. 2011;134(Pt 6):1751–64. doi:10.1093/brain/awr059.

    Article  PubMed  Google Scholar 

  91. Olino TM, McMakin DL, Dahl RE, et al. “I won, but I’m not getting my hopes up”: depression moderates the relationship of outcomes and reward anticipation. Psychiatry Res. 2011;194(3):393–5. doi:10.1016/j.pscychresns.2011.04.009.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Pizzagalli DA, Holmes AJ, Dillon DG, et al. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry. 2009;166(6):702–10. doi:10.1176/appi.ajp.2008.08081201.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Robinson OJ, Cools R, Carlisi CO, et al. Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder. Am J Psychiatry. 2012;169(2):152–9. doi:10.1176/appi.ajp.2011.11010137.

    Article  PubMed  Google Scholar 

  94. Stoy M, Schlagenhauf F, Sterzer P, et al. Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram. J Psychopharmacol. 2012;26(5):677–88. doi:10.1177/0269881111416686.

    Article  CAS  PubMed  Google Scholar 

  95. Forbes EE, Olino TM, Ryan ND, et al. Reward-related brain function as a predictor of treatment response in adolescents with major depressive disorder. Cogn Affect Behav Neurosci. 2010;10(1):107–18. doi:10.3758/CABN.10.1.107.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Benedetti F, Mayberg HS, Wager TD, et al. Neurobiological mechanisms of the placebo effect. J Neurosci. 2005;25(45):10390–402.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Sara Costi, Katherine Collins & Dan V. Iosifescu

  2. Adult Psychopharmacology Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Katherine Collins & Dan V. Iosifescu

  3. Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel

    Michael Davidson

  4. Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Dan V. Iosifescu

  5. Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Dan V. Iosifescu

Authors
  1. Sara Costi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Davidson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dan V. Iosifescu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dan V. Iosifescu.

Ethics declarations

Conflict of Interest

Dr. Sara Costi reports no conflicts of interest.

Dr. Katherine Collins is a consultant for ProPhase. She received research support from NIH via a T32 post-doctoral fellowship (T32MH096678).

Dr. Michael Davidson received grant support and/or travel support and/or speaker fees and/or consultant fees from Servier and Takeda, and holds stocks in Minerva Neuroscience and CTR.

Over the past 5 years, Dr. Dan Iosifescu has been a consultant for Avanir, Axome, CNS Response, INSYS Therapeutics, Lundbeck, Otsuka, Servier, and Sunovion and has received research support through the Icahn School of Medicine at Mount Sinai from Alkermes, Astra Zeneca, Brainsway, Euthymics, Neosync, Roche, and Shire. Dr. Iosifescu’s research is supported by NIH contracts N01HHSN271201100006I and N01HHSN271201200006I.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Mood and Anxiety Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Costi, S., Collins, K., Davidson, M. et al. Using Placebo Response to Pain as a Predictor of Placebo Response in Mood Disorders. Curr Behav Neurosci Rep 3, 360–367 (2016). https://doi.org/10.1007/s40473-016-0092-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40473-016-0092-3

Keywords

Search

Navigation